EP3193873A1 - Composition pour administration orale et procédés de prévention des addictions par administration intranasale - Google Patents

Composition pour administration orale et procédés de prévention des addictions par administration intranasale

Info

Publication number
EP3193873A1
EP3193873A1 EP14902242.8A EP14902242A EP3193873A1 EP 3193873 A1 EP3193873 A1 EP 3193873A1 EP 14902242 A EP14902242 A EP 14902242A EP 3193873 A1 EP3193873 A1 EP 3193873A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
drug
cmax
auc
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14902242.8A
Other languages
German (de)
English (en)
Other versions
EP3193873A4 (fr
Inventor
Manish S. Shah
Ray J. Difalco
Stefan Aigner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspirion Delivery Sciences LLC
Original Assignee
Inspirion Delivery Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspirion Delivery Technologies LLC filed Critical Inspirion Delivery Technologies LLC
Publication of EP3193873A1 publication Critical patent/EP3193873A1/fr
Publication of EP3193873A4 publication Critical patent/EP3193873A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention provides orally administrable pharmaceutical compositions and methods of deterring abuse by intranasal administration.
  • While pain medications, medications to reduce or eliminate anxiety attacks (psychotherapeutic drugs), stimulants and sleeping pills can be safe, effective, and therapeutically useful when administered properly, such drugs are susceptible to abuse.
  • examples of such compositions include but are not limited to ROXICODONE® (oxycodone tablets), OXYCONTIN® (oxycodone tablets), DILAUDID® (hydromorphone tablets), OPANA® and OPANA ER® (oxymorphone tablets), MS CONTIN® (morphine tablets), CONCERTA®, METHYLIN®, RITALIN®, RITALIN LA®, and EQUASYM KL® (methylphenidate tablets and capsules), FOCALIN® (dexmethylphenidate capsules), ADDERALL®, DEXEDRINE®, and DEXTROSTAT® (dextroamphetamine tablets and capsules), VYVANSE® (lisdexamfetamine capsules), ATIVAN® (lorazepam), XANAX® (alprazolam), and VALIUM®
  • a sense of euphoria or "high” can be experienced with high serum concentrations of these drugs. Individuals seeking to abuse these drugs will often tamper with oral dosage forms containing the drugs to achieve this "high.” For example, a large amount of tablets can be placed in a liquid to form a solution, and abusers either consume the liquid or more often filter and inject the solution. These tablets can also be crushed into a powder or small particle sizes and snorted intranasally.
  • Nasal insufflation which is another term for the inhalation of substances through the nose, is a common and harmful practice among abusers. Long-term practice of nasal insufflation can result in permanent damage to nasal tissue and increased incidence of toxicity and overdose.
  • compositions which minimize the ability for abuse, and when administered properly, provide an adequate and effective amount of drug.
  • the present invention addresses the need for an orally administrable drug product which, compared to conventional formulations, decreases the ability of an individual to achieve a "high" or euphoria effect through injection or insufflation.
  • the present invention provides an orally administrable pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC of the drug achieved after a time period is lower than the Cmax and/or AUC of the drug achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition not containing one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation.
  • the present invention also provides an orally administrable pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC achieved after a time period is no more than about 250% of the Cmax and/or AUC achieved after oral administration of the pharmaceutical composition in an intact form.
  • the present invention provides an orally administrable pharmaceutical composition of the present invention comprises a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC of a major metabolite of the drug achieved after intranasal administration after a time period is higher than the Cmax and/or AUC of the major metabolite of the drug achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition not containing one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation after the same time period.
  • the present invention provides an orally administrable pharmaceutical composition of the present invention comprises a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the ratio of the AUC of the drug to the AUC of a major metabolite of the drug (drug:major metabolite) achieved after intranasal administration after a time period is lower than the ratio of the AUC of the drug to the AUC of a major metabolite of the drug (drug:major metabolite) achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition not containing one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation after the same time period.
  • the present invention provides a method of treating, preventing, reducing the occurrence of, decreasing the severity or degree of, and/or reducing the signs and/or symptoms of a disease or condition in a subject in need thereof, wherein the disease or condition is selected from the group consisting of: pain, sleep disorders, anxiety, attention deficit hyperactivity disorder, narcolepsy, and depression in a subject in need thereof, comprising administering to the subject an orally administrable pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC of the drug achieved after a time period is lower than the Cmax and/or AUC of the drug achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition not containing one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal ins
  • the present invention provides a method of treating, preventing, reducing the occurrence of, decreasing the severity or degree of, and/or reducing the signs and/or symptoms of a disease or condition in a subject in need thereof, wherein the disease or condition is selected from the group consisting of: pain, sleep disorders, anxiety, attention deficit hyperactivity disorder, narcolepsy, and depression in a subject in need thereof, comprising administering to the subject an orally administrable pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC achieved after a time period is no more than about 250% of the Cmax and/or AUC achieved after oral administration of the pharmaceutical composition in an intact form.
  • the present invention provides a method of treating, preventing, reducing the occurrence of, decreasing the severity or degree of, and/or reducing the signs and/or symptoms of a disease or condition in a subject in need thereof, wherein the disease or condition is selected from the group consisting of: pain, sleep disorders, anxiety, attention deficit hyperactivity disorder, narcolepsy, and depression in a subject in need thereof, comprising administering to the subject an orally administrable pharmaceutical composition of the present invention comprises a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC of a major metabolite of the drug achieved after intranasal administration after a time period is higher than the Cmax and/or AUC of the major metabolite of the drug achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition
  • the orally administrable pharmaceutical composition of the present invention comprises a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC of the drug achieved after a time period is lower than the Cmax and/or AUC of the drug achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition not containing one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation after the same time period.
  • the time period is selected from the group consisting of: 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours.
  • the Cmax and/or AUC achieved after intranasal administration is at least 5% lower, alternatively at least 10% lower, alternatively at least 15% lower, alternatively at least 20% lower, alternatively at least 25% lower, alternatively at least 30% lower, alternatively at least 35% lower, alternatively at least 40% lower, alternatively at least 45% lower, alternatively at least 50% lower, alternatively at least 55% lower, or alternatively at least 60% lower than the Cmax and/or AUC achieved after intranasal administration of an orally bioequivalent composition after the same period of time.
  • the area under the curve, or "AUC” refers to the area under the serum concentration curve, or the integral of the blood serum concentration of the drug substance over a period of time.
  • Cmax refers to the maximum or peak concentration observed after administration.
  • the AUC and/or Cmax achieved after a period of time refers to the AUC and/or Cmax, respectively, calculated after a period of time after administration.
  • the period of time is about 30 minutes to about 24 hours after administration.
  • the period of time is selected from the group consisting of about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 8 hours, about 12 hours, and about 24 hours and the AUC and/or Cmax are calculated at any of these time points after administration.
  • the period of time is selected from the group consisting of: about 0.5 hours, 1 hour, and 2 hours.
  • the AUC may refer to the "AUCo-t".
  • the term “AUC 0-t” refers to the AUC from time zero ("0") to "t” wherein T is the last time point with measurable concentration for individual formulation.
  • the present invention also provides an orally administrable pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC of the drug achieved after intranasal administration is no more than about 250% of the Cmax and/or AUC achieved after oral administration of the pharmaceutical composition in an intact form after the same period of time.
  • the Cmax and/or AUC is measured after a time period selected from the group consisting of: 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after administration.
  • the AUC refers to AUCo-t-
  • the Cmax and/or AUC achieved after intranasal administration is no more than about 200%, alternatively no more than about 175%, alternatively no more than about 150% of the Cmax and/or AUC achieved after oral administration of the pharmaceutical composition in an intact form after the same period of time.
  • the orally administrable pharmaceutical composition of the present invention comprises a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUC of a major metabolite of the drug achieved after intranasal administration after a time period is higher than the Cmax and/or AUC of the major metabolite of the drug achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition not containing one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation after the same time period.
  • the time period is selected from the group consisting of: 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours.
  • the Cmax and/or AUC of a major metabolite of the drug after intranasal administration of the pharmaceutical composition of the present invention is at least 5% higher, alternatively at least 10% higher, alternatively at least 15% higher, alternatively at least 20% higher, alternatively at least 25% higher, alternatively at least 30% higher, than the Cmax and/or AUC of the major metabolite of the drug achieved after intranasal administration of an orally bioequivalent composition.
  • the orally administrable pharmaceutical composition of the present invention comprises a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the ratio of the AUC of the drug to the AUC of a major metabolite of the drug (drug:major metabolite) achieved after intranasal administration after a time period is lower than the ratio of the AUC of the drug to the AUC of a major metabolite of the drug (drug:major metabolite) achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition not containing one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation after the same time period.
  • the time period is selected from the group consisting of: 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours.
  • the ratio (drug:major metabolite) after intranasal administration of the pharmaceutical composition of the present invention is at least 5% lower, alternatively at least 10% lower, alternatively at least 15% lower, alternatively at least 20% lower, than the ratio (drug:major metabolite) achieved after intranasal administration of an orally bioequivalent composition.
  • a "orally bioequivalent" drug composition refers to a pharmaceutical composition which contains the same drug(s) and which, when administered orally in intact form, has an AUC and/or Cmax within the range of 80 to 125% of the AUC and/or Cmax of the reference drug composition when administered orally in intact form.
  • the bioequivalent drug composition comprises the same drug and same amount of drug, but it may comprise different pharmaceutically acceptable excipients or a different amount of pharmaceutically acceptable excipients.
  • the orally bioequivalent drug composition does not contain one or pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation.
  • the composition is "physically compromised" when it is in a form other than an intact form. This can be achieved by various means such as by chewing, chopping, grinding, crushing, or placing into solvents ex vivo, such as those containing an alcohol (e.g., ethyl alcohol) and/or water.
  • the physically compromised composition is in a chopped, ground, or crushed form.
  • a pharmaceutical composition may be physically compromised in a number of ways, including but not limited to use of a pill crusher, a pill splitter, a mortar and pestle, a solid object such as a hammer or a spoon, a sharp object such as a razor, a grinder such as a coffee bean grinder, or a blender.
  • the average particle size of the physically compromised pharmaceutical composition is less than 6 mm, alternatively less than 5 mm, alternatively less than 4 mm, alternatively less than 3 mm, alternatively less than 2 mm, alternatively less than 1 mm, alternatively less than 0.5 mm, alternatively less than 0.25 mm.
  • drug includes any compound which has pharmacological or biological activity.
  • a drug may comprise an active pharmaceutical ingredient or a salt, ester, or derivative thereof.
  • the drug can include, but is not limited to analgesics, anti-inflammatory agents, anti-helminthics, anti-arrhythmic agents, anti-asthma agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-dementia agents, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, immunosuppressants, antiprotozoal agents, anti-thyroid agents, anti-tussives, anxiolytics, sedatives, hypnotics, neuroleptics, neuroprotective agents, ⁇ -blockers, cardie ino
  • the drug or drugs will be one that is often abused, such as central nervous system stimulants and depressants.
  • central nervous system stimulants include, but are not limited amphetamines and agents such as cocaine.
  • central nervous depressants include, but are not limited to opioids, barbiturates, benzodiazepines, and other anxiety and sleep medications. Examples of combinations of two drugs include oxycodone and morphine.
  • the composition may comprise an opioid and an opioid antagonist such as naltrexone.
  • opioids include, but are not limited to the following: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine,
  • opioids include fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, morphine, hydroxycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, and dihydrocodeinone.
  • More preferred opioids include oxycodone, hydrocodone, codeine, morphine, oxymorphone and hydromorphone, and pharmaceutically acceptable salts and esters thereof.
  • the most particularly preferred opioids are oxycodone, oxymorphone, and morphine and pharmaceutically acceptable salts thereof.
  • a metabolite is a compound derived from the parent drug through Phase I and/or Phase II metabolic pathways.
  • a major metabolite of a drug may refer to a metabolite which in the human plasma accounts for > 10 % of the parent drug systemic exposure or administered dose.
  • the major metabolite may refer to active or inactive metabolites.
  • compositions of the present invention comprise morphine or a salt thereof.
  • Morphine also known as (5 ⁇ ,6 ⁇ )-7,8- didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol, is an example of a potent opioid analgesic used in the treatment of acute, chronic, and severe pain.
  • Salts of morphine include, but are not limited to sulfate, sulfate pentahydrate, hydrochloride, hydrochloride trihydrate, meconate, valerate, acetate, citrate, bitartrate, stearate, phthalate, hydrobromide, hydroiodide, mucate, nitrate, salicylate, phenylpropionate, phosphate, methyliodide, isobutyrate, hypophosphite, tannate, tartrate, methylbromide, methylsulfonate, and those disclosed in EP 0137600, which is incorporated herein by reference.
  • the composition comprises morphine sulfate or morphine sulfate pentahydrate.
  • Major metabolites of morphine include morphine-3-glucuronide (M3G), morphine-6-glucuronide (M6G), hydromorphone, normorphine (NM) and minor metabolites such as morphine-3,6- diglucuronide, morphine-3-ethereal sulfate, normorphine-6-glucuronide, and normorphine-3-glucuronide.
  • Morphine-6-glucuronide (M6G) a major metabolite of morphine, is formed by glucuronidation. M6G and morphine both demonstrate analgesic activity.
  • compositions of the present invention comprise oxycodone or a salt thereof.
  • Oxycodone also known as (5R,9f?,13S,14S)- 4,5a-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, is an opioid analgesic used for the treatment of pain.
  • Major metabolites of oxycodone include noroxycodone, a oxycodol, ⁇ oxycodol, oxymorphone, a oxymorphol, ⁇ oxymorphol, noroxymorphone, a noroxycodol, ⁇ noroxycodol, noroxymorphone, 14- hydroxydihydrocodeine, and 14-hydroxydihydromorphine.
  • Oxymorphone and noroxycodone are the most commonly known major metabolites of oxycodone.
  • compositions of the present invention comprise oxymorphone or a salt thereof.
  • Oxymorphone also known as 14- hydroxydihydromorphinone and 4, 5a-e poxy-3, 14-di hydroxy- 17-methylmorphinan-6- one, is an opioid analgesic used for the treatment of pain.
  • Major metabolites of oxymorphone include oxymorphone-3-glucuronide and 6-hydroxy-oxymorphone.
  • compositions of the present invention comprise hydrocodone or a salt thereof.
  • Hydrocodone which is also known as 4,5a- epoxy-3-methoxy-17-methylmorphinan-6-one, is an opioid analgesic used for the treatment of pain.
  • Major metabolites of hydrocodone include norhydrocodone and hydromorphone.
  • compositions of the present invention comprise hydromorphone or a salt thereof.
  • Hydromorphone which is also known as 4,5-a-epoxy-3-hydroxy-17-methyl morphinan-6-one, is an opioid analgesic.
  • Major metabolites of hydromorphone include hydromorphone-3-glucuronide, hydromorphone-3-glucoside and dihydroisomorphine-6-glucuronide.
  • the compositions of the present invention comprise codeine or a salt thereof.
  • Codeine which is also known as a (5 ⁇ ,6 ⁇ )-7,8- didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol, is an opioid used for its analgesic, antitussive, antidiarrheal, antihypertensive, anxiolytic, antidepressant, sedative and hypnotic properties.
  • Major metabolites of codeine include codeine-6- glucuronide (C6G), norcodeine, hydrocodone, morphine, morphine-3-glucuronide, morphine-6-glucuronide, and normorphine.
  • compositions of the present invention comprise a barbiturate or a salt thereof.
  • barbiturates include, but are not limited to mephobarbital (which is sometimes marketed under the tradename MEBARAL®) and pentobarbital sodium (which is sometimes marketed under the tradename NEMBUTAL®). Barbiturates are often prescribed to treat anxiety, tension, and sleep disorders.
  • compositions of the present invention comprise a benzodiazepine or a salt or derivative thereof.
  • benzodiazepines and benzodiazepine derivatives include, but are not limited to diazepam (sometimes marketed under the tradename VALIUM®), alprazolam (sometimes marketed under the tradename XANAX®), lorazepam (sometimes marketed under the tradename ATIVAN®, triazolam (sometimes marketed under the tradename HALCION®), and estazolam (sometimes marketed under the tradename PROSOM®).
  • Benzodiazepines are often prescribed to treat anxiety, acute stress reactions, and panic attacks.
  • Alprazolam which is also known as 8-chloro-1 -methyl-6-phenyl-4/-/- [1 , 2, 4]triazolo[4,3-a][1 , ⁇ benzodiazepine, is a short acting anxiolytic.
  • Major metabolites of alprazolam include, but are not limited to 4-hydroxyalprazolam and a- hydroxyalprazolam.
  • Lorazepam which is also known as (RS)-7-Chloro-5-(2-chlorophenyl)- 3-hydroxy-1 ,3-dihydro-2H-1 ,4-benzodiazepin-2-one, is an anxiolytic agent having intermediate duration of action.
  • Major metabolites of lorazepam include, but are not limited to, 3-O-phenolic glucuronide and lorazepam glucuronide.
  • Diazepam which is also known as 7-chloro-1 ,3-dihydro- 1-methyl-5-phenyl-1 ,4-benzodiazepin-2(3/-/)-one, is a commonly used anxiolytic.
  • Major metabolites of diazepam include, but are not limited to desmethyldiazepam, esmethyldiazepam, oxazepam, and temazepam.
  • the compositions comprise a CNS depressant such as zaleplon, which is sometimes marketed under the tradename SONATA®, and Zolpidem, which is sometimes marketed under the tradename AMBIEN®.
  • the compositions of the present invention comprise a central nervous stimulant or salt thereof.
  • Central nervous stimulants are often used to increase mental alertness, and they can results in feelings of exhilaration and energy. Stimulants often increase heart rate, blood pressure and metabolism.
  • Amphetamines such as methylphenidate (sometimes marketed under the tradename RITALIN®) and dextroamphetamine (sometimes marketed under the tradenames ADDERALL® and DEXEDRINE®) are often prescribed for the treatment of narcolepsy, attention-deficit hyperactivity disorder, and depression that has not responded to other treatments.
  • Examples of such central nervous stimulants include, but are not limited to, amphetamines such as methylphenidate, dextroamphetamine, and lisdexamfetamine.
  • Methylphenidate which is also known as methyl phenyl(piperidin-2- yl)acetate, is a drug often used for treatment of narcolepsy, attention- deficit/hyperactivity disorder, and depression.
  • Major metabolites of methylphenidate include but are not limited to ethylphenidate, ritalinic acid (a-phenyl-2-piperidine acetic acid), hydroxymethylphenidate, and hydroxyritalinic acid.
  • Dextroamphetamine which is also known as (2S)-1 -phenylpropan-2- amine, is a drug used for treatment of narcolepsy, attention-deficit/hyperactivity disorder, and depression.
  • Major metabolites of dextroamphetamine include but are not limited to 4-hydroxyamphetamine, benzoic acid, phenylacetone, hippuric acid, 4- hydroxynorephedrine, and norephedrine.
  • Lisdexamfetamine also known as lisdexamfetamine, is another stimulant. It is a prodrug of phenethylamine and amphetamines such as dextroamphetamine.
  • the present invention provides for compositions comprising one or more drugs.
  • the compositions comprise one or more opioids.
  • the present invention also provides for compositions comprising one or more opioids, wherein the compositions do not comprise an opioid antagonist or any other drug that is not an opioid agonist.
  • the present invention provides for compositions comprising one or more drugs but not comprising any adverse agent.
  • Adverse agents refer to agents which reduce or eliminate one or more pharmacological effects of the drug or agents which cause an undesired physiological reaction, such as emesis.
  • Adverse agents include, but are not limited to antagonists such as opioid antagonists, mucous membrane irritants, and emetics.
  • the present invention provides compositions which do not comprise naloxone or naltrexone.
  • Preferred embodiments of the invention include a drug and amounts as follows: oxycodone or a pharmaceutically acceptable salt thereof, which is present in an amount of about 5 mg to about 400 mg; morphine or a pharmaceutically acceptable salt thereof, which is present in an amount of about 15 mg to about 800 mg; hydromorphone or a pharmaceutically acceptable salt thereof, which is present in an amount of about 1 mg to about 64 mg; hydrocodone or a pharmaceutically acceptable salt thereof, which is present in an amount of about 5 mg to about 400 mg; and oxymorphone or a pharmaceutically acceptable salt thereof, which is present in an amount of about 4 mg to about 80 mg.
  • compositions of the present invention comprise one or more pharmaceutically acceptable excipients.
  • pharmaceutically acceptable excipients include but are not limited to plasticizers, anti-adhesive, inert fillers, lipophilic agents and pigments used in a known manner.
  • anti-adhesive are metallic stearates, microcrystalline cellulose, calcium phosphate, AEROSIL® 200, and talc.
  • Fillers/diluents/binders may be incorporated such as sucrose, sorbitol, mannitol, various grades of lactose, various grades of microcrystalline cellulose, dextrins, maltodextrins, starches or modified starches, sodium phosphate, calcium phosphate, calcium carbonate, gelatin, polyvinylpyrrolidone, and sodium carboxymethylcellulose.
  • Disintegrants may be used such as cellulose derivatives, including microcrystalline cellulose, low-substituted hydroxypropyl cellulose, croscarmellose sodium, alginic acid, insoluble polyvinlypyrrolidone, and sodium carboxymethyl starch.
  • Glidants and lubricants may be incorporated such as stearic acid, metallic stearates such as magnesium stearate, talc, waxes, and glycerides with high inciting temperatures, colloidal silica, sodium stearyl fumarate, polyethyleneglycols, and alkyl sulphates.
  • Surfactants may be employed such as non-ionic (various grades of polysorbate); anionic such as docusate sodium and sodium lauryl sulfate, and cationic such as benzalkonium chloride.
  • An example of an amphoteric surfactant is 1 ,2-diacyl-L- phosphatidylcholine.
  • the preferred surfactants are TWEEN® 80, BRIJ®, and Nanoxyl-100.
  • Other appropriate pharmaceutically acceptable excipients may include colorants, flavoring agents, pH adjusting agents, solubilizing agents, wetting agents, solvent resistant agents and buffering agents.
  • the composition comprises one or more of the following types of pharmaceutically acceptable excipients: disintegrants, filler/diluent/binders, glidants and lubricants.
  • the composition comprises a mixture of one or more pharmaceutically excipients.
  • the composition comprises a mixture of a sugar alcohol such as mannitol, a lubricant such as magnesium stearate, and microcrystalline cellulose.
  • compositions of the present invention comprise one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation .
  • Nasal insufflation may be deterred in a number of ways, including but not limited to providing a high or euphoric effect which is substantially the same as or less than the euphoric effect achieved by oral administration of an intact dosage form and/or a physically compromised dosage form.
  • Another way to deter abuse by nasal insufflation is by providing an undesirable or adverse effect, such as nasal irritation or damage to the nasal mucosa. Substantially the same means within 20% and preferably within 10%.
  • Euphoria is a high or feeling of extreme elation, which is often experienced after an abuser is administered a pharmaceutical composition containing a central nervous system drug.
  • the amount or intensity of euphoria, or the euphoric effect can be measured in a number of different ways. Methods or techniques of measuring euphoria are sometimes similar to methods or techniques of measuring other conditions, such as pain. For example, the amount or intensity of euphoria can be measured in a numerical or linear scale, and the person experiencing the euphoria can quantify or rate the amount or intensity of the euphoria.
  • the amount or intensity of euphoria can be measured on a scale from 0 to 10, wherein a high amount of euphoria is designated by the number 10, and no euphoria is designated by the number 0.
  • the amount or intensity of euphoria can be measured on a linear scale, wherein one end of the line represents no euphoria, and the opposite end of the line represents a high amount of euphoria.
  • the one or pharmaceutically acceptable excipients may be in an amount sufficient to deter abuse by nasal insufflation when the composition comprises an active ingredient and one or more pharmaceutically acceptable excipients, wherein the ratio of the amount of pharmaceutically acceptable excipients in the composition to the amount of pharmaceutically acceptable excipient in an orally bioequivalent composition is greater than 1 :1. In some embodiments, the ratio is about 2:1 or greater, preferably about 2.5:1 of greater, more preferably about 3:1 or greater, more preferably about 3.5:1 or greater, and most preferably about 4:1 or greater. In some embodiments, the ratio is about 5:1 or greater.
  • the one or pharmaceutically acceptable excipients may be in an amount sufficient to deter abuse by nasal insufflation when the composition comprises one or more pharmaceutically acceptable excipients in an amount of at least 40%, alternatively at least 45%, alternatively at least 50%, alternatively at least 55%, alternatively at least 60%, alternatively at least 65%, alternatively at least 70%, alternatively at least 75%, alternatively at least 80%, alternatively at least 85%, alternatively at least 90%, alternatively at least 95% by weight of the total weight of the composition.
  • the composition comprises one or more pharmaceutically acceptable excipients in an amount of about 75% or more, alternatively about 80% or more, alternatively about 85% or more, or alternatively about 90% or more by weight of the total weight of the composition.
  • the bioequivalent composition not configured to deter abuse comprises one or more pharmaceutically acceptable excipients in an amount less than the amount present in a composition of the present composition.
  • the orally bioequivalent composition which in some embodiments is a bioequivalent composition not configured to deter abuse, comprises one or more pharmaceutically acceptable excipients in an amount of less than about 90%, alternatively about 85% or less, alternatively about 80% or less, alternatively about 75% or less, alternatively about 70% or less, alternatively about 65% or less, alternatively about 60% or less, by weight of the total weight of the composition.
  • the one or pharmaceutically acceptable excipients may be in an amount sufficient to deter abuse by nasal insufflation when the composition comprises the active ingredient and the one or more pharmaceutically acceptable excipients in a ratio of pharmaceutically acceptable excipien active ingredient of 1 :1 or more, alternatively 2:1 or more, alternatively 3:1 or more, alternatively 4:1 or more, or alternatively 5:1 or more.
  • the pharmaceutical composition may be formulated for immediate release and/or extended release characteristics.
  • extended release is used to refer to a composition which is formulated to provide for the gradual release of an active ingredient over an extended period of time, preferably over 2 to 48 hours, more preferably over 4 to 36 hours, and most preferably over 6 to 24 hours.
  • extended release includes controlled release and delayed release.
  • an extended release portion preferably ⁇ 25%, more preferably ⁇ 20%, of the active ingredient is released in the first hour from the extended release portion; preferably 15-50%, more preferably 20- 45%, of the active ingredient is released in the first two (2) hours from the extended release portion; preferably 40-80%, more preferably 45-75%, of the active ingredient is released in the first four (4) hours from the extended release portion; and preferably >75%, more preferably >80%, of the active ingredient is released after eight (8) hours from the extended release portion.
  • the pharmaceutical composition is formulated for immediate release.
  • immediate release is used to refer to a pharmaceutical composition which is formulated to release about 80% or more of an active ingredient after 4 hours, more preferably after 2 hours, and most preferably after 1 hour after oral administration.
  • the pharmaceutical composition is formulated to release about 80% or more, more preferably about 90% or more, even more preferably about 95% of the active ingredient in the pharmaceutical composition after about 1 hour after oral administration of the unit dosage form (for example, after swallowing the tablet or capsule or other dosage form).
  • the pharmaceutical composition can be in any pharmaceutical dosage form, including, but not limited to a tablet, a capsule, a micro tablet, granules, pellets, a lollipop, a lozenge and a coated capsule.
  • the pharmaceutical composition comprises a tablet dosage form.
  • the present invention also provides methods of administering compositions of the present invention.
  • the present invention provides a method of treating, preventing, reducing the occurrence of, decreasing the severity or degree of, and/or reducing the signs and/or symptoms of a disease or condition in a subject in need thereof, comprising administering to the subject a composition of the present invention.
  • the disease or condition includes any disease or condition which would benefit from administration of a drug, including but not limited to analgesics, antiinflammatory agents, anti-helminthics, anti-arrhythmic agents, anti-asthma agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-dementia agents, antidepressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, antihypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, immunosuppressants, anti-protozoal agents, anti-thyroid agents, anti-tussives, anxiolytics, sedatives, hypnotics, neuroleptics, neuroprotective agents, ⁇ -blockers, cardie inotropic agents, cell adhesion inhibitors, corticosteroids, cytokine receptor activity modulators, diuretics, anti-Parkinson'
  • the disease or conditions is selected from the group consisting of: pain, sleep disorders (such as insomnia), anxiety, attention deficit hyperactivity disorder, narcolepsy, and depression.
  • the disease or condition includes, but not limited to, pain, chronic pain; acute pain; and/or pain associated with, secondary to, or caused by conditions such as osteoarthritis, rheumatoid arthritis, fibromyalgia, migraines and other headaches, back-related disorders, shingles, stiffened joints, physical trauma, cardiovascular conditions, cancer, sciatica, kidney stones, appendicitis, neuralgia, pancreatitis, gout, endometriosis, stomach ulcers, Crohn's Disease, and post-operative conditions.
  • compositions of the prevent invention may be administered at a frequency of one or more times every day. In some embodiments, the composition is administered one, two, or three times daily.
  • the following study was conducted to test a Formulation containing 60 mg morphine sulfate pentahydrate and about 500 mg of pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients comprise about 400 mg of a mixture of mannitol, AVICEL® PH 102 (microcrystalline cellulose) and magnesium stearate.
  • the study was a randomized, double-blind study of 26 human subjects.
  • the Formulation was crushed, and the following mean exposures (AUCo-t) were observed.
  • Example 1 The following study compares the bioavailability and abuse potential of the Formulation of Example 1 and a Comparative Formulation (bioequivalent composition) containing morphine sulfate pentahydrate.
  • the Formulation of Example 1 contains 60 mg of morphine sulfate pentahydrate and about 500 mg of pharmaceutically acceptable excipients.
  • the Comparative Formulation contains 60 mg of morphine sulfate pentahydrate and about 100 mg of pharmaceutically acceptable excipients.
  • the study is a randomized, double-blind study of human subjects. The Formulation of Example 1 and the Comparative Formulation are crushed. After intranasal administration, he following mean exposures (AUCo-t) are observed.
  • AUCo-t mean exposures
  • the Comparative Formulation which contains less excipient, results in higher levels of morphine (MOR), lower levels of morphine 6-glucuronide (M6G), and a high ratio of MOR:M6G (compared to the Formulation of Example 1 ).
  • the Formulation of Example 1 which contains more excipient, displays low levels of morphine, high levels of M6G, and a low ratio of MOR/M6G.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour administration orale comprenant un médicament et un ou plusieurs excipients pharmaceutiquement acceptables en une quantité suffisante pour prévenir une addiction par insufflation nasale, laquelle composition pharmaceutique est conçue de telle sorte que lorsque la composition pharmaceutique est administrée par voie intranasale sous forme physiquement compromise à un sujet, la Cmax et/ou l'ASC du médicament obtenues après une période de temps est inférieure à la Cmax et/ou l'ASC du médicament obtenues après administration intranasale d'une forme physiquement compromise d'une composition biologiquement équivalente par voie orale ne contenant pas un ou plusieurs excipients pharmaceutiquement acceptables en une quantité suffisante pour prévenir l'addiction par insufflation nasale.
EP14902242.8A 2014-09-15 2014-09-15 Composition pour administration orale et procédés de prévention des addictions par administration intranasale Withdrawn EP3193873A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/055616 WO2016043698A1 (fr) 2014-09-15 2014-09-15 Composition pour administration orale et procédés de prévention des addictions par administration intranasale

Publications (2)

Publication Number Publication Date
EP3193873A1 true EP3193873A1 (fr) 2017-07-26
EP3193873A4 EP3193873A4 (fr) 2018-05-30

Family

ID=55533589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14902242.8A Withdrawn EP3193873A4 (fr) 2014-09-15 2014-09-15 Composition pour administration orale et procédés de prévention des addictions par administration intranasale

Country Status (3)

Country Link
EP (1) EP3193873A4 (fr)
CA (1) CA2961460A1 (fr)
WO (1) WO2016043698A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064122A1 (en) * 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
CA2477004C (fr) * 2002-02-22 2011-05-10 Thomas Piccariello Nouveaux composes pharmaceutiques a liberation prolongee destines a empecher la consommation abusive de substances controlees
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2007087452A2 (fr) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci
ZA200807571B (en) * 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
BRPI0815387B8 (pt) * 2007-08-13 2021-05-25 Abuse Deterrent Pharmaceutical Llc composição farmacêutica, método para fazer uma composição farmacêutica e uso da composição farmacêutica

Also Published As

Publication number Publication date
EP3193873A4 (fr) 2018-05-30
WO2016043698A1 (fr) 2016-03-24
CA2961460A1 (fr) 2016-03-24

Similar Documents

Publication Publication Date Title
US20220031693A1 (en) Tamper Resistant Immediate Release Formulations
US20150005334A1 (en) Abuse deterrent compositions and methods of use
EP2755638B1 (fr) Formulations à libération immédiate résistant au détournement d'utilisation
EP2755640B1 (fr) Formulations pharmaceutiques inviolables
US20160106680A1 (en) Abuse Deterrent Immediate Release Formulation
US20030191147A1 (en) Opioid antagonist compositions and dosage forms
CA2408106A1 (fr) Compositions d'antagoniste opioide et formes de dosage
CN103415285A (zh) 包含阿片样激动剂和被隔离的拮抗剂的药物组合物
AU2001259458B2 (en) Opioid antagonist compositions and dosage forms
US11141414B2 (en) Pharmaceutical compositions comprising a pH-dependent component and pH-raising agent
AU2001259458A1 (en) Opioid antagonist compositions and dosage forms
CA2847613A1 (fr) Formulations a liberation immediate resistant au detournement d'utilisation
US10729685B2 (en) Orally administrable compositions and methods of deterring abuse by intranasal administration
US10420726B2 (en) Abuse deterrent compositions and methods of use
WO2016043698A1 (fr) Composition pour administration orale et procédés de prévention des addictions par administration intranasale

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180426

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/137 20060101ALI20180420BHEP

Ipc: A61K 31/485 20060101ALI20180420BHEP

Ipc: A61K 9/36 20060101AFI20180420BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSPIRION DELIVERY SCIENCES LLC

17Q First examination report despatched

Effective date: 20190909

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210723